Product/Composition:- | Albendazole suspension |
---|---|
Strength:- | 200 mg/5 mL |
Form:- | Suspension |
Reference Brands:- | Albenza(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Albendazole inhibits helminth microtubule polymerization by binding to β-tubulin, disrupting cell division and nutrient uptake. It effectively treats intestinal and systemic worm infections. Benefits include broad-spectrum activity, ease of oral administration, and high efficacy, especially in pediatric use. When used appropriately, it is effective in managing parasitic diseases.
Albendazole suspension is approved in the EU and US for treating helminth infections, including neurocysticercosis and hydatid disease, primarily in pediatric populations. In the EU, brands are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval relies on extensive clinical data. Both regions require detailed regulatory dossiers, including clinical trial data, manufacturing information, and robust pharmacovigilance plans. For expert support navigating regulatory landscapes, visit PharmaTradz. We ensure compliance with European and US standards, facilitating seamless market access for albendazole suspension.